AlloVir (ALVR) Competitors $3.33 +0.08 (+2.46%) As of 05/20/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALVR vs. CNTX, INCR, ANL, CLSD, MCRB, BYSI, VTVT, UNCY, IOBT, and BMEAShould you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include Context Therapeutics (CNTX), InterCure (INCR), Adlai Nortye (ANL), Clearside Biomedical (CLSD), Seres Therapeutics (MCRB), BeyondSpring (BYSI), vTv Therapeutics (VTVT), Unicycive Therapeutics (UNCY), IO Biotech (IOBT), and Biomea Fusion (BMEA). These companies are all part of the "pharmaceutical products" industry. AlloVir vs. Context Therapeutics InterCure Adlai Nortye Clearside Biomedical Seres Therapeutics BeyondSpring vTv Therapeutics Unicycive Therapeutics IO Biotech Biomea Fusion Context Therapeutics (NASDAQ:CNTX) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations. Do analysts recommend CNTX or ALVR? Context Therapeutics currently has a consensus target price of $6.00, indicating a potential upside of 757.14%. Given Context Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Context Therapeutics is more favorable than AlloVir.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Context Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals have more ownership in CNTX or ALVR? 14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 2.8% of Context Therapeutics shares are held by insiders. Comparatively, 32.1% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is CNTX or ALVR more profitable? Context Therapeutics' return on equity of -58.76% beat AlloVir's return on equity.Company Net Margins Return on Equity Return on Assets Context TherapeuticsN/A -58.76% -55.80% AlloVir N/A -71.03%-61.27% Does the media refer more to CNTX or ALVR? In the previous week, Context Therapeutics had 4 more articles in the media than AlloVir. MarketBeat recorded 4 mentions for Context Therapeutics and 0 mentions for AlloVir. Context Therapeutics' average media sentiment score of 0.64 beat AlloVir's score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Context Therapeutics Positive AlloVir Neutral Which has better earnings & valuation, CNTX or ALVR? Context Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContext TherapeuticsN/AN/A-$23.96M-$0.31-2.26AlloVirN/AN/A-$190.42M-$20.23-0.16 Does the MarketBeat Community prefer CNTX or ALVR? Context Therapeutics received 1 more outperform votes than AlloVir when rated by MarketBeat users. Likewise, 80.00% of users gave Context Therapeutics an outperform vote while only 57.45% of users gave AlloVir an outperform vote. CompanyUnderperformOutperformContext TherapeuticsOutperform Votes2880.00% Underperform Votes720.00% AlloVirOutperform Votes2757.45% Underperform Votes2042.55% Which has more volatility & risk, CNTX or ALVR? Context Therapeutics has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. SummaryContext Therapeutics beats AlloVir on 13 of the 16 factors compared between the two stocks. Get AlloVir News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVR vs. The Competition Export to ExcelMetricAlloVirBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.79M$2.94B$5.40B$8.47BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-0.1631.0926.7519.95Price / SalesN/A408.39393.46114.60Price / CashN/A168.6838.2534.62Price / Book0.113.296.834.58Net Income-$190.42M-$72.17M$3.22B$248.19M7 Day Performance2.46%6.29%5.26%2.14%1 Month Performance-52.36%9.76%13.27%16.20%1 Year Performance-81.81%-27.19%17.58%7.87% AlloVir Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVRAlloVirN/A$3.33+2.5%N/A-81.6%$16.79MN/A-0.16110High Trading VolumeCNTXContext Therapeutics2.6966 of 5 stars$0.78-0.1%$5.40+592.4%-65.9%$69.96MN/A-0.867Earnings ReportINCRInterCure0.8621 of 5 stars$1.52-4.4%N/A-52.7%$69.27M$238.85M0.00350Gap DownANLAdlai Nortye1.4915 of 5 stars$1.88+1.4%$9.00+380.0%-85.2%$69.19M$5M0.00127Gap DownHigh Trading VolumeCLSDClearside Biomedical2.5386 of 5 stars$0.89+3.7%$5.25+489.6%-33.9%$68.82M$1.66M-1.9830Earnings ReportMCRBSeres Therapeutics3.511 of 5 stars$7.88+11.8%$73.67+834.9%-56.6%$68.81M$126.33M-34.26330Positive NewsBYSIBeyondSpringN/A$1.70+1.3%N/A-36.1%$68.58M$1.88M0.0080Gap DownVTVTvTv Therapeutics1.8606 of 5 stars$21.46+3.2%$35.50+65.4%-26.4%$68.46M$1.02M-4.749Earnings ReportUNCYUnicycive Therapeutics3.2799 of 5 stars$0.57+2.8%$5.50+872.6%-43.4%$68.22M$680,000.00-0.589News CoveragePositive NewsEarnings ReportAnalyst RevisionIOBTIO Biotech3.1045 of 5 stars$1.03+3.0%$9.33+806.1%-25.4%$67.86MN/A-0.7530News CoverageAnalyst RevisionGap UpBMEABiomea Fusion2.7174 of 5 stars$1.77+8.6%$22.60+1,176.8%-87.6%$66.50MN/A-0.4450 Related Companies and Tools Related Companies CNTX Alternatives INCR Alternatives ANL Alternatives CLSD Alternatives MCRB Alternatives BYSI Alternatives VTVT Alternatives UNCY Alternatives IOBT Alternatives BMEA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALVR) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALVR Stock Free ALVR Stock Alerts